

JosÃ© Golay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6191694/publications.pdf>

Version: 2024-02-01

95
papers

6,632
citations

76294

40
h-index

62565

80
g-index

95
all docs

95
docs citations

95
times ranked

7800
citing authors

#	ARTICLE	IF	CITATIONS
1	Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo. <i>Journal of Immunology</i> , 2003, 171, 1581-1587.	0.4	519
2	From the bench to the bedside: ways to improve rituximab efficacy. <i>Blood</i> , 2004, 104, 2635-2642.	0.6	494
3	CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. <i>Blood</i> , 2001, 98, 3383-3389.	0.6	395
4	The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. <i>Blood</i> , 2003, 102, 956-963.	0.6	344
5	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 412-422.	2.2	273
6	M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro. <i>Journal of Immunology</i> , 2009, 182, 4415-4422.	0.4	227
7	Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. <i>Blood</i> , 2013, 122, 3482-3491.	0.6	206
8	Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab. <i>Journal of Immunology</i> , 2011, 186, 3762-3769.	0.4	198
9	Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. <i>Blood</i> , 2011, 118, 3301-3310.	0.6	188
10	Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 375-381.	2.0	181
11	Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. <i>Haematologica</i> , 2007, 92, 952-959.	1.7	165
12	Mutations in v-myb alter the differentiation of myelomonocytic cells transformed by the oncogene. <i>Cell</i> , 1990, 63, 1287-1297.	13.5	159
13	Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts. <i>Bone Marrow Transplantation</i> , 2007, 40, 785-791.	1.3	148
14	Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy. <i>Haematologica</i> , 2015, 100, 77-86.	1.7	147
15	Genetic Modification of Human T Cells with CD20: A Strategy to Purify and Lyse Transduced Cells with Anti-CD20 Antibodies. <i>Human Gene Therapy</i> , 2000, 11, 611-620.	1.4	126
16	Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. <i>Experimental Hematology</i> , 2009, 37, 616-628.e2.	0.2	121
17	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. <i>MAbs</i> , 2013, 5, 826-837.	2.6	105
18	Minimally manipulated whole human umbilical cord is a rich source of clinical-grade human mesenchymal stromal cells expanded in human platelet lysate. <i>Cytotherapy</i> , 2011, 13, 786-801.	0.3	104

#	ARTICLE	IF	CITATIONS
19	A single point mutation in the v-ets oncogene affects both erythroid and myelomonocytic cell differentiation. <i>Cell</i> , 1988, 55, 1147-1158.	13.5	99
20	A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. <i>Annals of Hematology</i> , 2010, 89, 185-190.	0.8	99
21	The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. <i>Haematologica</i> , 2006, 91, 176-83.	1.7	99
22	Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays. <i>Archives of Biochemistry and Biophysics</i> , 2012, 526, 146-153.	1.4	95
23	Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy. <i>Journal of Immunology</i> , 2013, 190, 231-239.	0.4	95
24	Characterization of CD20-Transduced T Lymphocytes as an Alternative Suicide Gene Therapy Approach for the Treatment of Graft-Versus-Host Disease. <i>Human Gene Therapy</i> , 2004, 15, 63-76.	1.4	94
25	Rituximab-mediated antibody-dependent cellular cytotoxicity against neoplastic B cells is stimulated strongly by interleukin-2. <i>Haematologica</i> , 2003, 88, 1002-12.	1.7	90
26	FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. <i>Haematologica</i> , 2007, 92, 1127-1130.	1.7	89
27	Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies. <i>Blood</i> , 2017, 129, 2636-2644.	0.6	86
28	Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. <i>Blood</i> , 2003, 101, 4589-4597.	0.6	76
29	Small Dose of Rituximab for Graves Orbitopathy: New Insights Into the Mechanism of Action. <i>JAMA Ophthalmology</i> , 2012, 130, 122.	2.6	75
30	Effect of alemtuzumab on neoplastic B cells. <i>Haematologica</i> , 2004, 89, 1476-83.	1.7	72
31	The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. <i>Haematologica</i> , 2011, 96, 1822-1830.	1.7	69
32	Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. <i>Blood</i> , 2011, 117, 510-518.	0.6	57
33	A Human Immunodeficiency Virus Type 1 polGene-Derived Sequence (cPPT/CTS) Increases the Efficiency of Transduction of Human Nondividing Monocytes and T Lymphocytes by Lentiviral Vectors. <i>Human Gene Therapy</i> , 2002, 13, 1793-1807.	1.4	56
34	Nucleolin, a Novel Partner for the Myb Transcription Factor Family That Regulates Their Activity. <i>Journal of Biological Chemistry</i> , 2000, 275, 4152-4158.	1.6	54
35	A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells. <i>Journal of Biological Chemistry</i> , 2000, 275, 6499-6508.	1.6	53
36	Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33+ acute lymphoblastic leukaemias in vitro and in vivo. <i>British Journal of Haematology</i> , 2005, 128, 310-317.	1.2	52

#	ARTICLE	IF	CITATIONS
37	Feasibility and Safety of Adoptive Immunotherapy with CIK Cells after Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1603-1607.	2.0	49
38	Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2070-2078.	2.0	48
39	The CCL3 Family of Chemokines and Innate Immunity Cooperate In Vivo in the Eradication of an Established Lymphoma Xenograft by Rituximab. <i>Journal of Immunology</i> , 2007, 178, 6616-6623.	0.4	46
40	Human neutrophils express low levels of Fc γ RIIIA, which plays a role in PMN activation. <i>Blood</i> , 2019, 133, 1395-1405.	0.6	46
41	Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death. <i>Blood</i> , 2010, 116, 3372-3373.	0.6	41
42	Clinical grade expansion of MSCs. <i>Immunology Letters</i> , 2015, 168, 222-227.	1.1	41
43	The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable <i>in vitro</i> activity against chronic lymphocytic leukemia B cells with CD20 antibodies. <i>Haematologica</i> , 2017, 102, e400-e403.	1.7	41
44	The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. <i>Antibodies</i> , 2020, 9, 58.	1.2	41
45	Regulatory domains of the A-Myb transcription factor and its interaction with the CBP/p300 adaptor molecules. <i>Biochemical Journal</i> , 1997, 324, 729-736.	1.7	37
46	Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b. <i>Haematologica</i> , 2010, 95, 260-269.	1.7	36
47	The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2V617F myeloproliferative neoplasm cells. <i>Experimental Hematology</i> , 2012, 40, 634-645.e10.	0.2	36
48	Acquired immunodeficiency syndrome-associated lymphomas are efficiently lysed through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by rituximab. <i>British Journal of Haematology</i> , 2002, 119, 923-929.	1.2	35
49	Functional transfer of CD40L gene in human B-cell precursor ALL blasts by second-generation SIN lentivectors. <i>Gene Therapy</i> , 2004, 11, 85-93.	2.3	35
50	The Polo-Like Kinase 1 (PLK1) Inhibitor NMS-P937 Is Effective in a New Model of Disseminated Primary CD56+ Acute Monoblastic Leukaemia. <i>PLoS ONE</i> , 2013, 8, e58424.	1.1	31
51	Direct involvement of CD56 in cytokine-induced killer-mediated lysis of CD56+ hematopoietic target cells. <i>Experimental Hematology</i> , 2014, 42, 1013-1021.e1.	0.2	31
52	The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs. <i>Cytotherapy</i> , 2009, 11, 403-413.	0.3	30
53	Givinostat and hydroxyurea synergize <i>in vitro</i> to induce apoptosis of cells from JAK2V617F myeloproliferative neoplasm patients. <i>Experimental Hematology</i> , 2013, 41, 253-260.e2.	0.2	30
54	Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies. <i>Journal of Immunology</i> , 2016, 196, 3199-3211.	0.4	30

#	ARTICLE	IF	CITATIONS
55	Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. <i>Haematologica</i> , 2014, 99, e94-e97.	1.7	29
56	A Novel Method Using Blinatumomab for Efficient, Clinical-Grade Expansion of Polyclonal T Cells for Adoptive Immunotherapy. <i>Journal of Immunology</i> , 2014, 193, 4739-4747.	0.4	24
57	Role of Fc Core Fucosylation in the Effector Function of IgG1 Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
58	Rapid retroviral infection of human haemopoietic cells of different lineages: efficient transfer in fresh T cells. <i>British Journal of Haematology</i> , 1998, 103, 449-461.	1.2	22
59	Lepidopteran cells, an alternative for the production of recombinant antibodies?. <i>MAbs</i> , 2012, 4, 294-309.	2.6	22
60	The sensitivity of acute lymphoblastic leukemia cells carrying the t(12;21) translocation to campath-1H-mediated cell lysis. <i>Haematologica</i> , 2006, 91, 322-30.	1.7	21
61	C-myb, but not B-myb, Upregulates Type I Collagen Gene Expression in Human Fibroblasts. <i>Journal of Investigative Dermatology</i> , 1999, 112, 191-196.	0.3	19
62	Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia. <i>Molecular Cancer</i> , 2011, 10, 42.	7.9	18
63	Characterization of the c-Myb-responsive Region and Regulation of the Human Type I Collagen $\alpha 2$ Chain Gene by c-Myb. <i>Journal of Biological Chemistry</i> , 2003, 278, 1533-1541.	1.6	17
64	Rituximab induces different but overlapping sets of genes in human B-lymphoma cell lines. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 273-286.	2.0	17
65	Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?. <i>Frontiers in Immunology</i> , 2020, 11, 609063.	2.2	17
66	A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myb transcriptional regulation. <i>Blood</i> , 2000, 96, 1013-1020.	0.6	16
67	Utility of routine evaluation of sterility of cellular therapy products with or without extensive manipulation: Best practices and clinical significance. <i>Cytotherapy</i> , 2018, 20, 262-270.	0.3	15
68	The A-Myb Transcription Factor in Neoplastic and Normal B Cells. <i>Leukemia and Lymphoma</i> , 1997, 26, 271-279.	0.6	14
69	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. <i>Antibodies</i> , 2020, 9, 17.	1.2	14
70	The DNA Binding Domain of the A-MYB Transcription Factor Is Responsible for Its B Cell-specific Activity and Binds to a B Cell 110-kDa Nuclear Protein. <i>Journal of Biological Chemistry</i> , 1997, 272, 24921-24926.	1.6	13
71	Detection of a transcriptional block in the first intron of the human c-myb gene. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 159-164.	1.0	12
72	Complement in antibody therapy: friend or foe?. <i>Blood</i> , 2009, 114, 5247-5248.	0.6	12

#	ARTICLE	IF	CITATIONS
73	Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. <i>Experimental Hematology</i> , 2010, 38, 259-269.e2.	0.2	12
74	Monoclonal Antibody Monitoring: Clinically Relevant Aspects, A Systematic Critical Review. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 45-56.	1.0	12
75	Identification of Two Novel Isoforms of the ZNF162 Gene: A Growing Family of Signal Transduction and Activator of RNA Proteins. <i>Genomics</i> , 1997, 42, 268-277.	1.3	11
76	Direct targeting of cancer cells with antibodies: What can we learn from the successes and failure of unconjugated antibodies for lymphoid neoplasias?. <i>Journal of Autoimmunity</i> , 2017, 85, 6-19.	3.0	11
77	Chemokines and antagonists in non-Hodgkin's lymphoma. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 621-635.	1.5	8
78	Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. <i>Cytotherapy</i> , 2018, 20, 1077-1088.	0.3	8
79	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories. <i>Cytotherapy</i> , 2016, 18, 481-486.	0.3	7
80	A comprehensive report of long-term stability data for a range ATMPs: A need to develop guidelines for safe and harmonized stability studies. <i>Cytotherapy</i> , 2022, 24, 544-556.	0.3	7
81	Key Features Defining the Disposition of Bispecific Antibodies and Their Efficacy In Vivo. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 57-63.	1.0	6
82	Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. <i>Cytokine</i> , 1994, 6, 544.	1.4	5
83	Final Analysis of a Multicenter Pilot Phase 2 Study of Cytokine Induced Killer (CIK) Cells for Patients with Relapse after Allogeneic Transplantation. <i>Blood</i> , 2016, 128, 1160-1160.	0.6	5
84	Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use. <i>Cytotherapy</i> , 2022, 24, 334-343.	0.3	5
85	Hematopoietic Progenitor Cells From Patients with Chronic Mountain Sickness Lack the JAK2V617F Mutation, Show Hypersensitivity to Erythropoietin and Are Inhibited by Statins.. <i>Blood</i> , 2009, 114, 1894-1894.	0.6	3
86	A Multicenter Phase II Study of Sequential Administration of Unmanipulated DLI and Donor Derived Cytokine Induced Killer (CIK) Cells in HSCT Patients, Relapsed of Disease. <i>Blood</i> , 2015, 126, 3160-3160.	0.6	3
87	BL-01, an Fc-bearing, tetravalent CD20-CD5 bispecific antibody, redirects multiple immune cells to kill tumors in vitro and in vivo. <i>Cytotherapy</i> , 2022, 24, 161-171.	0.3	2
88	A-myb rescues murine B-cell lymphomas from IgM-receptor-mediated apoptosis through c-myctranscriptional regulation. <i>Blood</i> , 2000, 96, 1013-1020.	0.6	2
89	Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization. <i>Antibodies</i> , 2021, 10, 26.	1.2	1
90	Infusion of Donor Derived Cytokine Induced Killer Cells May Induce Clinical Remission with Limited GVHD in Patients Relapsing after Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2006, 108, 3698-3698.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Massive, Clinical Grade Expansion Of Polyclonal T Cells Using Blinatumomab For Adoptive Autologous Cellular Therapy Of CLL Patients. Blood, 2013, 122, 3272-3272.	0.6	1
92	Human Macrophages Phagocytose Rituximab Opsonised Leukemic Cells Via CD16, CD32 and CD64 but Do Not Mediate ADCC.. Blood, 2006, 108, 2507-2507.	0.6	1
93	Human Mesenchymal Stroma Cells (hMSCs) Expanded with Human Platelets Lysate Are Safe and Effective For the Treatment of Graft Versus Host Disease. Blood, 2008, 112, 1171-1171.	0.6	1
94	Comment on "Reduced T-Dependent Humoral Immunity in CD20-Deficient Mice". Journal of Immunology, 2013, 191, 5783-5783.	0.4	0
95	Potent Inhibition of EEC Colony Formation in JAK2V617F PV and ET by Low Doses of ITF2357, a New Histone Deacetylase Inhibitor.. Blood, 2006, 108, 2702-2702.	0.6	0